PI-04. Sepsis in early post-transplant period: new approaches to treatment

Cellular Therapy and Transplantation

article

Nune V. Matinyan¹  Tatyana V. Gorbunova¹  Timur T. Valiev¹  Irina O. Kostareva¹  Timur. Z. Aliev¹  Natalya A. Burlaka¹  Vasiliy P. Akimov Natalya A. Batmanova¹  Elena G. Gromova¹  Kirill I. Kirgizov¹  Svetlana R. Varfolomeeva¹ 

[1] Research Institute of Pediatric Oncology and Hematology, N. Blokhin National Medical Research Center of Oncology

关键词: Oncology/hematology;    pediatric;    HSCT;    sepsis;    endotoxin;    endotoxemia;    hemoperfusion.;   

DOI  :  10.18620/ctt-1866-8836-2022-11-3-1-132

学科分类：肿瘤学

来源: Universitaetsklinikum Hamburg - Eppendorf / University Medical Center Hamburg - Eppendorf

【 摘 要 】

Sepsis is a life-threatening clinical condition in immunocompromised patients, especially after hematopoietic stem cell transplantation (HSCT). Sepsis could lead to unregulated inflammation, causing multiple organ failure and hypercytokinemia with lethal outcome. Urgent hemosorbtion could be considered a potential option in complex therapy of sepsis after HSCT. Our aim was to estimate effectiveness of hemoperfusion with polymyxin B-immobilized cartridge (PMX-hemoperfusion) in the early posttransplant period.

【 授权许可】

CC BY